Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia. - Wikidata - wikimedia - TriplyDB

Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia.

Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia.

http://www.wikidata.org/entity/Q33401100

about

Advances in Diagnosis and Treatments for Immune Thrombocytopenia Role of romiplostim in splenectomized and nonsplenectomized patients with immune thrombocytopenia Bacterial Infections Following Splenectomy for Malignant and Nonmalignant Hematologic Diseases Immune thrombocytopenia Contemporary management of primary immune thrombocytopenia in adults Thrombopoietin receptor agonists in the treatment of immune thrombocytopenia: a clinician's perspective.Positioning new treatments in the management of immune thrombocytopenia The beta 1 tubulin R307H single nucleotide polymorphism is associated with treatment failures in immune thrombocytopenia (ITP).B cell depletion in immune thrombocytopenia reveals splenic long-lived plasma cells.Sustained remissions of immune thrombocytopenia associated with the use of thrombopoietin receptor agonists Management of primary immune thrombocytopenia, 2012: a survey of oklahoma hematologists-oncologists Immune thrombocytopenia -- what are the new treatment options?Pathophysiology and management of primary immune thrombocytopenia.Efficacy and safety of rituximab given at 1,000 mg on days 1 and 15 compared to the standard regimen to treat adult immune thrombocytopenia.Low-dose anti-CD20 veltuzumab given intravenously or subcutaneously is active in relapsed immune thrombocytopenia: a phase I study.The effect of rituximab on vaccine responses in patients with immune thrombocytopenia Rituximab versus splenectomy in persistent or chronic adult primary immune thrombocytopenia: an adjusted comparison of mortality and morbidity.Contemporary treatment of immune thrombocytopenia.Diagnosis and management of autoimmune cytopenias in childhood.Clinical practice: immune thrombocytopenia in paediatrics.Long-term follow-up of children with refractory immune thrombocytopenia treated with rituximab.Immune thrombocytopenia: recent progress in pathophysiology and treatment.Novel treatments for immune thrombocytopenia.Rituximab and three dexamethasone cycles provide responses similar to splenectomy in women and those with immune thrombocytopenia of less than two years duration.A review of the management of childhood immune thrombocytopenia: how can we provide an evidence-based approach?Management of thrombocytopenia.Aberrant frequency of IL-10-producing B cells and its association with Treg/Th17 in adult primary immune thrombocytopenia patients.The choice of second-line therapy in steroid-resistant immune thrombocytopenia: role of platelet kinetics in a single-centre long-term study.Long-term use of the thrombopoietin-mimetic romiplostim in children with severe chronic immune thrombocytopenia (ITP).Need for an improved vaccination rate in primary immune thrombocytopenia patients exposed to rituximab or splenectomy. A nationwide population-based study in France.A multicenter randomized open-label study of rituximab plus rhTPO vs rituximab in corticosteroid-resistant or relapsed ITP.Romiplostim as a treatment for immune thrombocytopenia: a review.Risk infection to spare bleeding? The quandary of splenectomy for immune thrombocytopenia.Rituximab leads to long remissions in patients with chronic immune thrombocytopenia A novel triple therapy for ITP using high-dose dexamethasone, low-dose rituximab, and cyclosporine (TT4).Initial Management of Childhood Acute Immune Thrombocytopenia: Single-Center Experience of 32 Years.Efficacy and Safety of Rituximab in Systemic Lupus Erythematosus and Sjögren Syndrome Patients With Refractory Thrombocytopenia: A Retrospective Study of 21 Cases.Relation of interleukin-10 Promoter Polymorphisms to Adult Chronic Immune Thrombocytopenic Purpura in a Cohort of Egyptian Population.B-cell hyperfunction in children with immune thrombocytopenic purpura persists after splenectomy.Remission and platelet responses with romiplostim in primary immune thrombocytopenia: final results from a phase 2 study.

P2860

Q26738630-D2FCE159-DF5D-485F-9568-84BBA4A91E81 Q26741269-4CAB2E80-AFBC-4B4C-948E-76530F2D8A3F Q26778773-0935D375-D6CB-4C94-AA1F-165AF2E7DB5E Q26830918-9AEA76BE-6D06-4348-809B-4A9C7C1B217E Q26853680-267FD4D3-A3DF-436C-A1D7-AC6ECD18CEC9 Q33402591-F08D16D9-37EC-46FA-B60C-A06739D44C44 Q33404095-BA2C6808-A374-425C-AFC1-50C6D6FC2D0C Q33404408-9D3D988B-0AF3-4481-A087-1CE7A34D0D7A Q33404838-1A32E124-0C9A-4F3E-B5C3-552F2F0BAC98 Q33406176-8B482B2F-143F-486F-8C50-C83850BDD7B0 Q33406264-61FEC2C6-6FB9-405F-98ED-AC22E73F1BC3 Q33407802-04F73BA9-577F-498F-BC21-E19D9C1A900F Q33407942-2EFDDBA5-CAFC-4F83-8A3A-825FD8C46068 Q33408621-6C9DED71-A80A-4354-A19C-C5031556BA52 Q33408915-2CEC1E43-599F-450C-A23F-7DB1D991680A Q33409067-345A7235-170A-47F6-8B5F-439DC825133E Q33410348-7B934D7F-EAA3-4A88-B163-A34F2D69D1A1 Q33410653-404421A8-507F-4EAB-A6E3-9025061ECBFF Q33411497-8D049885-2951-4941-8A1C-8A89A79797F7 Q33412475-EBD12A7B-D71A-4663-96C7-724C7DA0AAFB Q33413781-F7A6F91E-7732-4F00-8C18-E8F5CE800306 Q33413896-FCEC09E8-E76F-47C9-AD11-F0DDE5660C39 Q33414132-F5DBFABB-C789-4C71-82DB-C6ACD1DF10E4 Q33414722-D81B2E5B-5EF1-4F2C-ADA3-CA008C9081FA Q33414825-1D7C5270-9116-435F-95F5-B69CEEF4507E Q33416258-7A17EFA7-8DEB-4B53-A6FE-2F4207C7D8EE Q33416700-26858DF2-0BC7-48A8-909F-5B9A584ADCB8 Q33416947-9B6829E8-2CBC-47CD-9A4F-CD8F00F88A6B Q33418391-14EC3114-DB92-4BAA-A304-DBCFF0A56F3F Q33419605-DC64F1E4-7DE4-4CCE-A6B5-6782850C44EA Q33419712-E045DD46-6672-4F8A-A1DA-673C75CA0D82 Q33420059-D0F16A14-9A6A-4343-8B6A-464CB125174C Q33420393-5802C2B0-FDA9-49E2-9D11-7C414D1B264B Q33422731-6DAEDF34-7808-4FCE-9B50-E396E9808ED2 Q33422782-0988B925-A52E-4202-B44A-B15C4C41AA44 Q33424247-968F48DC-E856-43AA-826A-EFC4409E0247 Q33424691-6C7ABFD7-AE07-4D1A-98CF-E0D7382608F1 Q33426471-2DF35C4E-9012-40CA-A470-54871C1CF05F Q33426961-7DD7C5F4-D272-4035-A31B-B4158FF80EC7 Q33427336-525EBB29-B161-4EEA-8F72-1FB071F858CE

P2860

Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia.

http://www.wikidata.org/entity/Q33401100

description

2012 nî lūn-bûn

@nan

2012 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Outcomes 5 years after respons ...... with immune thrombocytopenia.

@ast

Outcomes 5 years after respons ...... with immune thrombocytopenia.

@en

type

label

Outcomes 5 years after respons ...... with immune thrombocytopenia.

@ast

Outcomes 5 years after respons ...... with immune thrombocytopenia.

@en

prefLabel

Outcomes 5 years after respons ...... with immune thrombocytopenia.

@ast

Outcomes 5 years after respons ...... with immune thrombocytopenia.

@en

P1433

Q33401100-EE4EA11C-9E98-417A-AEF3-6E6F280B90EA

P1476

Q33401100-A0B54483-8EC8-411F-AE3B-6B976BBAFA38

P2093

Q33401100-15543089-5A29-4786-A890-0DBBA6A6C09F

Q33401100-1F3CA62F-F41D-4196-B036-29332C079A48

Q33401100-2316C3D7-5787-4F4B-B4C6-AF6873345CE5

Q33401100-32391199-1062-4249-8E0D-AC378EEA15CF

Q33401100-49357C83-0862-44B6-A62D-4D99D4C4E288

Q33401100-73C68160-4CB2-4A97-B8DA-94D079DE055B

Q33401100-81090691-6120-4F1F-8307-4B1C73703256

Q33401100-B6707FB4-C6B0-4BFE-91EC-5F9E61274DB6

Q33401100-BF70C6D7-1533-408F-943B-54CEFF5AE0D2

Q33401100-CB055199-CD9A-4B5D-8410-F388BAB596CA

P2860

Q33401100-000388F4-63EE-46D4-8C39-A06BC06CE398

Q33401100-0529CA7C-63ED-4831-B144-D3BA17DA0673

Q33401100-0C6E2786-4482-4F2C-926F-BF103B6BFDA3

Q33401100-0E0152DF-24AF-4399-BA1A-D5D1FEA78539

Q33401100-11264CAE-A021-4E4F-8C44-B20B50495EA2

Q33401100-15956BAF-5848-416C-8DC8-5E1910EC8142

Q33401100-1A30F461-01C5-4658-BF0F-FC48369F6010

Q33401100-28848780-086C-47FA-9628-908E39418D8B

Q33401100-2E66B327-6A03-4827-88EA-4434F28AFB74

Q33401100-30E234C1-D922-4A84-8AAE-5BAAE42ADFAA

P304

Q33401100-F6A01F2D-6E72-4CC6-B61C-3CA1F7209318

P31

Q33401100-FBADC478-1B4E-43B1-8F37-1A28C9A0E8C5

P356

Q33401100-E6C25DBE-F126-4CE4-B6A7-A8B98A26BC5C

P407

Q33401100-36141AF1-5744-4948-B29E-5AF56076C878

P433

Q33401100-68F39DBC-82B2-44B1-B428-1758AEB366F0

P478

Q33401100-8EE7152B-AA23-4081-B9B4-91A844BFA4B6

P50

Q33401100-7E14BE88-BB38-4D8B-A990-9537F42DE0FC

Q33401100-8E203AAE-5A54-4C12-8514-642602CCDC67

P577

Q33401100-62127117-CCBE-48DB-B926-FE564A8D4F4B

P698

Q33401100-C8593DC0-C528-447E-B5EE-C68502868336

P921

Q33401100-7AC606F7-A5F7-45D2-84E4-12688724106A

P932

Q33401100-7C17C6B0-40C1-4A04-A6A9-3CF9E0A2DF97

P356

BLOOD-2011-11-393975

P1433

P1476

Outcomes 5 years after respons ...... with immune thrombocytopenia.

@en

P2093

Ellis Neufeld

http://www.w3.org/2001/XMLSchema#string

Julie Kanter

http://www.w3.org/2001/XMLSchema#string

Martin Lesser

http://www.w3.org/2001/XMLSchema#string

Mary J Ward

http://www.w3.org/2001/XMLSchema#string

Matthieu Mahévas

http://www.w3.org/2001/XMLSchema#string

Nichola Cooper

http://www.w3.org/2001/XMLSchema#string

Nino Mihatov

http://www.w3.org/2001/XMLSchema#string

Philippe Bierling

http://www.w3.org/2001/XMLSchema#string

Roberto Stasi

http://www.w3.org/2001/XMLSchema#string

Shalini Shenoy

http://www.w3.org/2001/XMLSchema#string

P2860

Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains

Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura.

A pilot study of the anti-CD20 monoclonal antibody rituximab in patients with refractory immune thrombocytopenia.

Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura.

B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia.

Treatment of relapsed idiopathic thrombocytopenic purpura with the anti-CD20 monoclonal antibody rituximab: a pilot study.

Long term follow-up after splenectomy performed for immune thrombocytopenic purpura (ITP).

B-cell compartment as the selective target for the treatment of immune thrombocytopenias.

Rituximab for immune cytopenia in adults: idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, and Evans syndrome.

Refractory autoimmune thrombocytopenic purpura: responses to treatment with a recombinant antibody to lymphocyte membrane antigen CD20 (rituximab).

P304

5989-5995

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2011-11-393975

http://www.w3.org/2001/XMLSchema#string

P407

P433

25

http://www.w3.org/2001/XMLSchema#string

P478

119

http://www.w3.org/2001/XMLSchema#string

P50

Bertrand Godeau

P577

2012-05-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22566601

http://www.w3.org/2001/XMLSchema#string

P921

thrombocytopenia

P932

3383014

http://www.w3.org/2001/XMLSchema#string